Literature DB >> 5049808

Response of patients with postencephalitic Parkinsonism to levodopa.

R C Duvoisin, J Lobo-Antunes, M D Yahr.   

Abstract

Thirty patients with postencephalitic Parkinsonism were treated with levodopa. In seven patients, treatment was withdrawn because of adverse reactions or insufficient benefit. Improvements observed in 26 patients who remained on treatment for a sufficient period to permit adequate assessment were comparable with those previously reported in Parkinson's disease. Some sequelae of encephalitis lethargica-notably, oculogyria and drooling-were appreciably improved in most patients affected, whereas choreoathetoid dyskinesias were aggravated by levodopa. Adventitious choreiform involuntary movements and behaviour disorders were the major side-effects. Patients with postencephalitic Parkinsonism may respond as well as patients with Parkinson's disease to levodopa but they develop both favourable responses and side-effects at a lower dosage and require careful dosage adjustments and close surveillance.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5049808      PMCID: PMC494109          DOI: 10.1136/jnnp.35.4.487

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  12 in total

1.  ENCEPHALITIS AND PARKINSONISM.

Authors:  R C DUVOISIN; M D YAHR
Journal:  Arch Neurol       Date:  1965-03

2.  The brain-stem lesions in Parkinsonism.

Authors:  J G GREENFIELD; F D BOSANQUET
Journal:  J Neurol Neurosurg Psychiatry       Date:  1953-11       Impact factor: 10.154

3.  L-dopa and oculogyric crises.

Authors:  O W Sacks; M Kohl
Journal:  Lancet       Date:  1970-07-25       Impact factor: 79.321

4.  Incontinent nostalgia induced by L-dopa.

Authors:  O W Sacks; M Kohl
Journal:  Lancet       Date:  1970-06-27       Impact factor: 79.321

5.  Side-effects of L-dopa in postencephalic parkinsonism.

Authors:  O W Sacks; M Kohl; W Schwartz; C Messeloff
Journal:  Lancet       Date:  1970-05-09       Impact factor: 79.321

6.  L-dopa in postencephalitic parkinsonism.

Authors:  D B Calne; G M Stern; D R Laurence; J Sharkey; P Armitage
Journal:  Lancet       Date:  1969-04-12       Impact factor: 79.321

7.  L-dopa for postencephalitic Parkinsonism.

Authors:  N Krasner; J M Cornelius
Journal:  Br Med J       Date:  1970-11-21

8.  Treatment of parkinsonism with levodopa.

Authors:  M D Yahr; R C Duvoisin; M J Schear; R E Barrett; M M Hoehn
Journal:  Arch Neurol       Date:  1969-10

9.  Analysis of deaths in Parkinson patients on long-term levodopa therapy.

Authors:  L Cote; M D Yahr; R C Duvoisin; A Wolf; W Marksbery
Journal:  Trans Am Neurol Assoc       Date:  1970

10.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

View more
  4 in total

1.  Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.

Authors:  C Colosimo; M Merello; A J Hughes; K Sieradzan; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

2.  Supranuclear gaze palsy and eyelid apraxia in postencephalitic parkinsonism.

Authors:  G K Wenning; K Jellinger; I Litvan
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 3.  Gene-environment interactions: key to unraveling the mystery of Parkinson's disease.

Authors:  Hui-Ming Gao; Jau-Shyong Hong
Journal:  Prog Neurobiol       Date:  2011-03-23       Impact factor: 11.685

4.  Standing on the shoulders of giants: 100 years of neurology and epidemic infections.

Authors:  Harriett Van Den Tooren; Mark A Ellul; Nicholas Ws Davies; Ava Easton; Angela Vincent; Tom Solomon; Benedict Daniel Michael
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-09-21       Impact factor: 10.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.